|
AstraZeneca ltd
parp1 inhibitors olaparib Parp1 Inhibitors Olaparib, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/parp+inhibitor+olaparib/parp+inhibitor+olaparib/pmc05716178-152-0-15 Average 90 stars, based on 1 article reviews
parp1 inhibitors olaparib - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
|
ApexBio
parp inhibitor (parpi or pi) 20 μm olaparib Parp Inhibitor (Parpi Or Pi) 20 μm Olaparib, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/parp+inhibitor+olaparib/parp+inhibitor++parpi+or+pi++20+%CE%BCm+olaparib/10__1091_slash_mbc__e18___10___0650-195-7-24 Average 90 stars, based on 1 article reviews
parp inhibitor (parpi or pi) 20 μm olaparib - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
|
ApexBio
parp inhibitor olaparib Parp Inhibitor Olaparib, supplied by ApexBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/parp+inhibitor+olaparib/parp+inhibitor+olaparib/pm30404833-137-4-7 Average 90 stars, based on 1 article reviews
parp inhibitor olaparib - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
|
AstraZeneca ltd
parp inhibitors with distinct binding profiles, particularly astrazeneca’s olaparib Parp Inhibitors With Distinct Binding Profiles, Particularly Astrazeneca’s Olaparib, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/parp+inhibitor+olaparib/parp+inhibitors+with+distinct+binding+profiles++particularly+astrazeneca%E2%80%99s+olaparib/10__1038_slash_scibx__2012__323-53-19-18 Average 90 stars, based on 1 article reviews
parp inhibitors with distinct binding profiles, particularly astrazeneca’s olaparib - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
|
LC Laboratories
papr1/2 inhibitor olaparib Papr1/2 Inhibitor Olaparib, supplied by LC Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/parp+inhibitor+olaparib/parp1+2+inhibitor+olaparib/pmc04298135-154-11-16 Average 90 stars, based on 1 article reviews
papr1/2 inhibitor olaparib - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
|
NSABP Foundation
parp inhibitor olaparib Parp Inhibitor Olaparib, supplied by NSABP Foundation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/parp+inhibitor+olaparib/parp+inhibitor+olaparib/pm28982747-119-42-34 Average 90 stars, based on 1 article reviews
parp inhibitor olaparib - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
|
Adooq Bioscience LLC
parp inhibitor olaparib  Parp Inhibitor Olaparib, supplied by Adooq Bioscience LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/parp+inhibitor+olaparib/parp+inhibitor+olaparib/pmc07900609-47-0-4 Average 90 stars, based on 1 article reviews
parp inhibitor olaparib - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
|
AstraZeneca ltd
oral parp inhibitor olaparib  Oral Parp Inhibitor Olaparib, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/parp+inhibitor+olaparib/oral+parp+inhibitor+olaparib/pmc07079537-14-0-2 Average 90 stars, based on 1 article reviews
oral parp inhibitor olaparib - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
|
AstraZeneca ltd
small-molecule parp inhibitor olaparib  Small Molecule Parp Inhibitor Olaparib, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/parp+inhibitor+olaparib/small+molecule+parp+inhibitor+olaparib/pmc03377106-193-13-17 Average 90 stars, based on 1 article reviews
small-molecule parp inhibitor olaparib - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
|
AstraZeneca ltd
oral poly(adp-ribose) polymerase (parp) inhibitor olaparib (lynparza - astrazeneca) Oral Poly(adp Ribose) Polymerase (Parp) Inhibitor Olaparib (Lynparza Astrazeneca), supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/parp+inhibitor+olaparib/oral+poly+adp+ribose++polymerase++parp++inhibitor+olaparib++lynparza+++astrazeneca+/pm37339094-6-10-17 Average 90 stars, based on 1 article reviews
oral poly(adp-ribose) polymerase (parp) inhibitor olaparib (lynparza - astrazeneca) - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
|
Biozol Diagnostica Vertrieb GmbH
parp inhibitor olaparib Parp Inhibitor Olaparib, supplied by Biozol Diagnostica Vertrieb GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/parp+inhibitor+olaparib/parp+inhibitor+olaparib/pmc06732317-44-6-9 Average 90 stars, based on 1 article reviews
parp inhibitor olaparib - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
|
Galen US Inc
parp-inhibitor olaparib Parp Inhibitor Olaparib, supplied by Galen US Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/parp+inhibitor+olaparib/parp+inhibitor+olaparib/10__1007_slash_s15013___020___3110___1-12-0-5 Average 90 stars, based on 1 article reviews
parp-inhibitor olaparib - by Bioz Stars,
2026-09
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Cell Reports
Article Title: Persistence of RNA transcription during DNA replication delays duplication of transcription start sites until G2/M
doi: 10.1016/j.celrep.2021.108759
Figure Lengend Snippet:
Article Snippet:
Techniques: Recombinant, Staining, Transfection, Random Primed, DNA Labeling, Imaging, DNA Library Preparation, Library Quantification, Western Blot, Reverse Transcription, Generated, Software
Journal: Journal of Ovarian Research
Article Title: Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
doi: 10.1186/s13048-020-00629-4
Figure Lengend Snippet: Abdominal CT showing the metastatic para-aortic lymph node. Notes: a pretreatment of Olaparib. b Six months posttreatment of Olaparib. c Nine months posttreatment of Olaparib
Article Snippet:
Techniques:
Journal: Journal of Ovarian Research
Article Title: Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
doi: 10.1186/s13048-020-00629-4
Figure Lengend Snippet: The tumor (arrow) in spleen disappeared. Notes: a pretreatment of Olaparib. b posttreatment of Olaparib
Article Snippet:
Techniques:
Journal: Journal of Ovarian Research
Article Title: Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
doi: 10.1186/s13048-020-00629-4
Figure Lengend Snippet: The metastatic para-aortic lymph node pointed with arrow. Notes: a pretreatment of Olaparib. b posttreatment of Olaparib
Article Snippet:
Techniques:
Journal: Journal of Ovarian Research
Article Title: Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
doi: 10.1186/s13048-020-00629-4
Figure Lengend Snippet: The hepatic metastatic pointed with arrow. Notes: a recurrence before chemotherapy. b partial response after chemotherapy/pretreatment of Olaparib. c progressive disease after using Olaparib. d partial response after chemotherapy
Article Snippet:
Techniques:
Journal: Journal of Ovarian Research
Article Title: Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
doi: 10.1186/s13048-020-00629-4
Figure Lengend Snippet: The metastatic para-aortic lymph node pointed with arrow. Notes: a recurrence before chemotherapy. b partial response after chemotherapy/pretreatment of Olaparib. c progressive disease after using Olaparib. d partial response after chemotherapy
Article Snippet:
Techniques:
Journal: Journal of Ovarian Research
Article Title: Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
doi: 10.1186/s13048-020-00629-4
Figure Lengend Snippet: The abdominal metastasis pointed with arrow. Notes: a recurrence before chemotherapy. b partial response after chemotherapy/pretreatment of Olaparib
Article Snippet:
Techniques:
Journal: Journal of Ovarian Research
Article Title: Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
doi: 10.1186/s13048-020-00629-4
Figure Lengend Snippet: The metastatic para-aortic lymph node pointed with arrow. Notes: a recurrence before chemotherapy. b partial response after chemotherapy/pretreatment of Olaparib
Article Snippet:
Techniques:
Journal: Journal of Ovarian Research
Article Title: Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
doi: 10.1186/s13048-020-00629-4
Figure Lengend Snippet: The metastatic in right pelvic pointed with arrow. Notes: a recurrence before chemotherapy. b partial response after chemotherapy/pretreatment of Olaparib
Article Snippet:
Techniques:
Journal: Journal of Ovarian Research
Article Title: Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
doi: 10.1186/s13048-020-00629-4
Figure Lengend Snippet: The metastatic vaginal stump pointed with arrow. Notes: a recurrence before chemotherapy. b partial response after chemotherapy/pretreatment of Olaparib
Article Snippet:
Techniques:
Journal: Journal of Ovarian Research
Article Title: Tumor burden is a potential marker of PARP inhibitor effects in ovarian cancer: a head-to-head observational series
doi: 10.1186/s13048-020-00629-4
Figure Lengend Snippet: Abdominal plain film of incomplete intestinal obstruction. Notes: progressive disease after using Olaparib
Article Snippet:
Techniques:
Journal: EMBO Molecular Medicine
Article Title: Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils
doi: 10.1002/emmm.201100176
Figure Lengend Snippet: Targeted therapies in oncogene-addicted cancers
Article Snippet: A Phase 1 trial conducted in 2009 demonstrated the anti-tumour activity of the
Techniques: